WOC
RXRX icon

West Oak Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

West Oak Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$49 Buy
1,000
+100
+11% +$525 ﹤0.01% 232
2025
Q2 		$46 Buy
900
+300
+50% +$1.47K ﹤0.01% 261
2025
Q1 		$32 Buy
+600
New +$4.37K ﹤0.01% 266

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

West Oak Capital's RXRX Position: Q3 2025 in Review

West Oak Capital increased its Recursion Pharmaceuticals (RXRX) stake by 11% in Q3 2025, buying an estimated $525 and bringing the position to 1,000 shares worth $49. The position accounts for ﹤0.01% of the portfolio, ranked #232.

West Oak Capital first reported a position in RXRX in Q1 2025 and has held it in 3 quarters since. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

  • West Oak Capital held 1,000 shares of Recursion Pharmaceuticals worth $49 as of Q3 2025.
  • West Oak Capital bought 100 Recursion Pharmaceuticals shares in Q3 2025, an estimated $525.
  • Recursion Pharmaceuticals made up ﹤0.01% of West Oak Capital's portfolio in Q3 2025, its #232 holding.
  • West Oak Capital first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • 322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on West Oak Capital's 13F filing for Q3 2025, filed 3 Oct 2025.